DM
Deerfield Management Portfolio holdings
AUM
$7.8B
1-Year Est. Return
76.63%
This Fund
S&P 500
1 Year Est. Return
+76.63%
AUM
$6.52B
AUM Growth
+$1.02B
(+18%)
Holding
173
Top Buys
| 1 | +$177M | |
| 2 | +$109M | |
| 3 | +$96.7M | |
| 4 |
Inspire Medical Systems
INSP
|
+$91.9M |
| 5 |
Cogent Biosciences
COGT
|
+$76M |
Top Sells
| 1 | +$250M | |
| 2 | +$74.9M | |
| 3 | +$47.7M | |
| 4 |
IDEAYA Biosciences
IDYA
|
+$42.6M |
| 5 |
United Therapeutics
UTHR
|
+$38.6M |
Sector Composition
| 1 | Healthcare | 91.92% |
| 2 | Real Estate | 0.38% |
| 3 | Financials | 0.07% |
| 4 | Consumer Staples | 0.07% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
IQVIA
IQV
$29.4B
| – | – |
-1,623
|
|
||
152
Pulmonx
LUNG
$54.9M
| – | – |
-1,890,000
|
|
||
153
Medpace
MEDP
$14.5B
| – | – |
-736
|
|
||
|
MREO
154
Mereo BioPharma
MREO
$51.3M
| – | – |
-6,710,429
|
|
||
155
Moderna
MRNA
$22.1B
| – | – |
-1,000,000
|
|
||
156
Neuropace
NPCE
$572M
| – | – |
-500,000
|
|
||
157
NovoCure
NVCR
$1.51B
| – | – |
-825,119
|
|
||
158
Oscar Health
OSCR
$4.89B
| – | – |
-11,649,591
|
|
||
159
Vaxcyte
PCVX
$8.75B
| – | – |
-225,000
|
|
||
160
RxSight
RXST
$305M
| – | – |
-888,950
|
|
||
161
Simulations Plus
SLP
$307M
| – | – |
-354,089
|
|
||
162
Universal Health Services
UHS
$11B
| – | – |
-1,597
|
|
||
163
PACS Group
PACS
$5.5B
| – | – |
-11,421
|
|